Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intramuscular ziprasidone mesylate
Intramuscular ziprasidone · 1 trial · 1 indication
BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline.
| Arm | Type | Description |
|---|---|---|
| Intramuscular ziprasidone | EXPERIMENTAL | - |
| Intramuscular haloperidol | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Intramuscular ziprasidone mesylate | DRUG | The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days. |
| Intramuscular haloperidol | DRUG | The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days. |
Inclusion Criteria: * Male or female Chinese subjects aged 18-65 years (including 65) at screening. * Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X). * Subjects who are in acute phase of schizophrenia and are appropriate to receive...
Top 15 of 16 competitors